X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Sun Pharma with TEVA PHARMACEUTICAL INDUSTRIES LTD. - Israel - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUN PHARMA vs TEVA PHARMA (Israel) - Comparison Results

SUN PHARMA    Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

TEVA PHARMA (Israel)
   Change

Teva Pharmaceuticals, established in 1901, is a global pharmaceutical company. The company is into development, production and marketing of a wide range of specialty medicines, generic and OTC products, active pharmaceutical ingredients (API) and nov... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 SUN PHARMA   TEVA PHARMA
EQUITY SHARE DATA
    SUN PHARMA
Mar-17
TEVA PHARMA
Dec-13
SUN PHARMA/
TEVA PHARMA
5-Yr Chart
Click to enlarge
High Rs8422,839-   
Low Rs5722,466-   
Sales per share (Unadj.) Rs131.61,629.2-  
Earnings per share (Unadj.) Rs32.7101.8-  
Cash flow per share (Unadj.) Rs38.0233.5-  
Dividends per share (Unadj.) Rs3.5089.09-  
Dividend yield (eoy) %0.53.4 14.7%  
Book value per share (Unadj.) Rs152.71,809.7-  
Shares outstanding (eoy) m2,399.26848.00-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x5.41.6 330.1%   
Avg P/E ratio x21.626.1 83.0%  
P/CF ratio (eoy) x18.611.4 163.9%  
Price / Book Value ratio x4.61.5 316.0%  
Dividend payout %10.787.5 12.2%   
Avg Mkt Cap Rs m1,696,8772,249,227 75.4%   
No. of employees `00017.544.9 39.0%   
Total wages/salary Rs m49,0230-   
Avg. sales/employee Rs Th18,028.330,738.8 58.7%   
Avg. wages/employee Rs Th2,798.80-   
Avg. net profit/employee Rs Th4,479.51,920.2 233.3%   
INCOME DATA
Net Sales Rs m315,7841,381,555 22.9%  
Other income Rs m6,2320-   
Total revenues Rs m322,0161,381,555 23.3%   
Gross profit Rs m100,893378,340 26.7%  
Depreciation Rs m12,648111,672 11.3%   
Interest Rs m3,99827,136 14.7%   
Profit before tax Rs m90,479239,531 37.8%   
Minority Interest Rs m01,088 0.0%   
Prior Period Items Rs m990-   
Extraordinary Inc (Exp) Rs m0-157,239 0.0%   
Tax Rs m12,116-2,924 -414.3%   
Profit after tax Rs m78,46286,305 90.9%  
Gross profit margin %31.927.4 116.7%  
Effective tax rate %13.4-1.2 -1,096.8%   
Net profit margin %24.86.2 397.7%  
BALANCE SHEET DATA
Current assets Rs m329,537933,097 35.3%   
Current liabilities Rs m178,870813,740 22.0%   
Net working cap to sales %47.78.6 552.3%  
Current ratio x1.81.1 160.7%  
Inventory Days Days7991 87.0%  
Debtors Days Days8396 86.8%  
Net fixed assets Rs m204,766451,246 45.4%   
Share capital Rs m2,3993,401 70.6%   
"Free" reserves Rs m363,9970-   
Net worth Rs m366,3971,534,646 23.9%   
Long term debt Rs m14,361706,420 2.0%   
Total assets Rs m614,1023,157,296 19.5%  
Interest coverage x23.69.8 240.5%   
Debt to equity ratio x00.5 8.5%  
Sales to assets ratio x0.50.4 117.5%   
Return on assets %13.43.6 373.7%  
Return on equity %21.45.6 380.8%  
Return on capital %24.84.9 503.7%  
Exports to sales %00-   
Imports to sales %00-   
Net fx Rs m19,6340-   
CASH FLOW
From Operations Rs m70,822220,148 32.2%  
From Investments Rs m-42,216-78,007 54.1%  
From Financial Activity Rs m-22,854-264,083 8.7%  
Net Cashflow Rs m6,107-121,942 -5.0%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for TEVA PHARMA (Israel) is United States Dollars. All data has been converted at 68.01 Rs / USD

Compare SUN PHARMA With: MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  

Compare SUN PHARMA With: BIOCON LTD  WOCKHARDT LTD.  DR. REDDYS LAB  DR. DATSONS LABS  DIVIS LABORATORIES  



Today's Market

Sensex Ends 262 Points Lower; Metal & Realty Stocks Fall(Closing)

Indian share markets ended lower today amid weak global cues. At the closing bell, the BSE Sensex finished lower by 262 points.

Related Views On News

SUN PHARMA Announces Quarterly Results (4QFY18); Net Profit Up 12.0% (Quarterly Result Update)

May 28, 2018 | Updated on May 28, 2018

For the quarter ended March 2018, SUN PHARMA has posted a net profit of Rs 16 bn (up 12.0% YoY). Sales on the other hand came in at Rs 70 bn (down 2.2% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

After Vakrangee and Manpasand, More Auditors May Soon Resign. To Protect Your Wealth, Avoid these Stocks(The 5 Minute Wrapup)

Jun 8, 2018

The change in auditing regulations can bring a big change in corporate governance behaviour in the mid and small-cap space.

Should You Get out of Small Caps Now... Before the Fall Worsens(Profit Hunter)

Jun 6, 2018

An almost zero-loss strategy that works best when markets correct. Don't let the current volatility overwhelm you. Focus on the fundamentals and long term, and buy stocks where quality meets value.

GST Will Not Solve Problem of High Prices of Petrol and Diesel(Vivek Kaul's Diary)

Jun 13, 2018

Though it will bring transparency in their pricing and that in itself will be a welcome move.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

Is Data Pointing Towards a Revival in the FMCG Sector?(Sector Info)

Jun 8, 2018

After several quarters of stress in the aftermath of demonetisation and the rollout of GST, this data is pointing towards revival in the India's rural FMCG industry.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SUN PHARMA SHARE PRICE


Jun 19, 2018 (Close)

TRACK SUN PHARMA

  • Track your investment in SUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SUN PHARMA - NOVARTIS COMPARISON

COMPARE SUN PHARMA WITH

MARKET STATS